Share This:
https://ntp.niehs.nih.gov/go/4959

TDMS Study 88133-06 Pathology Tables

NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02
Route: SKIN APPLICATION                                                                                           Time: 08:48:56

                                                            Final#2




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  15625-89-5

       Lock Date:  06/16/99

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include 002    0 MG/KG
                               Include 001    0 MG/KG
                               Include 004    0.75    MG/KG
                               Include 003    0.75    MG/KG
                               Include 006    1.5     MG/KG
                               Include 005    1.5     MG/KG
                               Include 008    3 MG/KG
                               Include 007    3 MG/KG
                               Include 010    6 MG/KG
                               Include 009    6 MG/KG
                               Include 012    12 MG/KG
                               Include 011    12 MG/KG























a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                                   1            2            1            1            3           
    Moribund Sacrifice                                                           1                                                  
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           14           12           14           14           12           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Hematopoietic Cell Proliferation                                           1 (7%)                                 6 (40%)     
      Infiltration Cellular                                                      1 (7%)                                 1 (7%)      
      Inflammation, Chronic Active                    15 (100%)    14 (93%)     13 (87%)     13 (87%)     14 (93%)      8 (53%)     
      Myelodysplasia                                                                                                    2 (13%)     
      Pigmentation                                    12 (80%)     15 (100%)    12 (80%)     13 (87%)     14 (93%)      4 (27%)     
      Hepatocyte, Necrosis                             4 (27%)      2 (13%)      1 (7%)       2 (13%)      1 (7%)       1 (7%)      
   Salivary Glands                                    (1)                                                              (1)          
      Parotid Gland, Infiltration Cellular                                                                              1 (100%)    
   Tooth                                              (1)          (4)          (3)          (1)          (3)          (2)          
      Fibrosis                                                                                                          1 (50%)     
      Inflammation, Chronic Active                                                            1 (100%)                              
      Malformation                                                               1 (33%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Inflammation, Chronic Active                                                                                      1 (7%)      
      Atrium, Thrombosis                                                                                                1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Pituitary Gland                                    (15)         (15)         (15)         (15)         (15)         (15)         
      Pars Distalis, Angiectasis                                                              1 (7%)                                
      Pars Distalis, Cyst                              1 (7%)                    2 (13%)      1 (7%)       2 (13%)      2 (13%)     
   Thyroid Gland                                      (15)         (15)         (15)         (15)         (15)         (15)         
      Infiltration Cellular                                                                                             1 (7%)      
      Inflammation, Chronic Active                                                                                      2 (13%)     
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Cyst                                             1 (7%)                                 1 (7%)                    1 (7%)      
      Inflammation, Chronic Active                                                            1 (7%)       1 (7%)                   
      Pigmentation                                     1 (7%)       1 (7%)                                                          
   Uterus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Hydrometra                                                    1 (7%)                    1 (7%)       1 (7%)       1 (7%)      
      Inflammation, Chronic Active                     1 (7%)                                                                       
      Cervix, Inflammation, Chronic Active                          1 (7%)                                                          
      Endometrium, Hyperplasia, Cystic                10 (67%)     11 (73%)      7 (47%)      8 (53%)      8 (53%)      9 (60%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (11)         (14)         (13)         (10)         (13)         (12)         
      Hematopoietic Cell Proliferation                                                                                  2 (17%)     
      Hyperplasia                                                                                                       2 (17%)     
      Inguinal, Hematopoietic Cell Proliferation                                                                        1 (8%)      
      Inguinal, Hyperplasia                                                                                             1 (8%)      
      Inguinal, Infiltration Cellular, Plasma Cell                                                                      2 (17%)     
      Inguinal, Myelodysplasia                                                                                          2 (17%)     
      Mediastinal, Hematopoietic Cell Proliferation                                                                     5 (42%)     
      Mediastinal, Infiltration Cellular                                         1 (8%)                                 2 (17%)     
      Mediastinal, Infiltration Cellular, Plasma                                                                                    
        Cell                                                                                                            2 (17%)     
   Lymph Node, Mandibular                             (15)         (15)         (15)         (15)         (15)         (15)         
      Hematopoietic Cell Proliferation                                           1 (7%)                                 6 (40%)     
      Hyperplasia                                      1 (7%)       3 (20%)      2 (13%)                   2 (13%)      3 (20%)     
      Hyperplasia, Plasma Cell                                                   1 (7%)                    1 (7%)                   
      Infiltration Cellular                                                      1 (7%)                                 1 (7%)      
      Infiltration Cellular, Plasma Cell                                         1 (7%)                                 2 (13%)     
      Inflammation, Chronic Active                                               1 (7%)                                             
      Myelodysplasia                                                                                                    1 (7%)      
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (15)         
      Hematopoietic Cell Proliferation                                                                                  4 (27%)     
      Infiltration Cellular                                                                                             2 (13%)     
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Atrophy                                                       1 (7%)       3 (20%)      1 (7%)       2 (13%)      1 (7%)      
      Hematopoietic Cell Proliferation                 7 (47%)     13 (87%)      9 (60%)      6 (40%)      8 (53%)     10 (67%)     
      Hyperplasia, Lymphoid                            2 (13%)      2 (13%)      2 (13%)                                            
      Infiltration Cellular                                                                                             1 (7%)      
      Myelodysplasia                                                                                                    2 (13%)     
   Thymus                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Atrophy                                                       1 (7%)       3 (20%)      2 (13%)      2 (13%)      3 (20%)     
      Thymocyte, Necrosis                                                        2 (13%)      1 (7%)                    1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Epidermis, Skin, Site of Application,                                                                                         
        Hyperplasia                                                              1 (7%)       4 (27%)     15 (100%)    15 (100%)    
      Epidermis, Skin, Site of Application,                                                                                         
        Hyperplasia, Focal                                                                    1 (7%)       1 (7%)       8 (53%)     
      Skin, Site of Application, Hyperkeratosis                                  1 (7%)       7 (47%)     14 (93%)     13 (87%)     
      Skin, Site of Application, Hyperplasia                                                               1 (7%)                   
      Skin, Site of Application, Inflammation,                                                                                      
         Chronic Active                                                                       3 (20%)     14 (93%)     12 (80%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Inflammation, Chronic Active                                               1 (7%)                                             
      Mediastinum, Infiltration Cellular                                                                                1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS FEMALE       0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Inflammation, Chronic Active                                               2 (13%)                                3 (20%)     
      Mineralization                                                                                                    1 (7%)      
      Nephropathy                                      4 (27%)                                                          1 (7%)      
      Renal Tubule, Cyst                                                                                                1 (7%)      
      Renal Tubule, Regeneration                                    1 (7%)                                 2 (13%)      1 (7%)      
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Natural Death                                      1                         3            1            2            4           
  Survivors                                                                                                                         
    Terminal Sacrifice                                14           15           12           14           13           11           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Basophilic Focus                                              1 (7%)                                                          
      Hematopoietic Cell Proliferation                 1 (7%)                    1 (7%)                                 6 (40%)     
      Infarct                                                       1 (7%)                                                          
      Infiltration Cellular                                                                                             5 (33%)     
      Inflammation, Acute                                           1 (7%)                                                          
      Inflammation, Chronic Active                     7 (47%)     10 (67%)      8 (53%)      8 (53%)      7 (47%)      8 (53%)     
      Mineralization                                                1 (7%)                                                          
      Myelodysplasia                                                                                                    1 (7%)      
      Pigmentation                                                  2 (13%)                                                         
      Hepatocyte, Necrosis                             2 (13%)      2 (13%)      2 (13%)                   1 (7%)       1 (7%)      
   Mesentery                                                                                              (1)          (1)          
      Fat, Necrosis                                                                                        1 (100%)     1 (100%)    
   Salivary Glands                                                              (1)          (1)                       (2)          
      Mandibular, Infiltration Cellular                                                                                 1 (50%)     
   Stomach, Forestomach                               (15)         (15)         (15)         (15)         (15)         (15)         
      Hyperkeratosis                                                             1 (7%)                    1 (7%)       3 (20%)     
      Inflammation, Chronic Active                                                                         1 (7%)                   
      Epithelium, Hyperplasia                                                                              1 (7%)                   
   Tooth                                              (1)          (3)          (1)          (2)          (1)          (1)          
      Inflammation, Chronic Active                                                            1 (50%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (15)         (15)         (15)         (15)         (15)         (15)         
      Atrium, Thrombosis                                                         1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    6                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ENDOCRINE SYSTEM - CONT                                                                                                             
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (15)         (15)         
      Hyperplasia                                                                                                       1 (7%)      
      Hypertrophy                                      7 (47%)      5 (33%)      9 (60%)      8 (53%)      5 (33%)      5 (33%)     
      Vacuolization Cytoplasmic                                                                                         1 (7%)      
   Pituitary Gland                                    (15)         (15)         (15)         (14)         (15)         (15)         
      Pars Distalis, Cyst                              2 (13%)      1 (7%)       1 (7%)       1 (7%)       1 (7%)       2 (13%)     
   Thyroid Gland                                      (15)         (15)         (15)         (15)         (15)         (15)         
      Inflammation, Chronic Active                                                                                      1 (7%)      
      Follicle, Cyst                                                             1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (15)         (15)         (15)         (15)         (15)         (15)         
      Atrophy                                                       1 (7%)                                                          
      Inflammation, Chronic Active                                  2 (13%)                                             3 (20%)     
      Myelodysplasia                                                                                                    1 (7%)      
      Bilateral, Hypospermia                                        1 (7%)                                                          
      Unilateral, Hypospermia                          4 (27%)                   3 (20%)      1 (7%)       1 (7%)       2 (13%)     
   Preputial Gland                                    (1)                                                              (1)          
      Inflammation, Chronic Active                                                                                      1 (100%)    
      Duct, Ectasia                                    1 (100%)                                                                     
   Testes                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Cyst                                             2 (13%)                   1 (7%)                                 1 (7%)      
      Bilateral, Germinal Epithelium, Degeneration                  1 (7%)                                                          
      Germinal Epithelium, Degeneration                                                                                 1 (7%)      
      Unilateral, Germinal Epithelium, Degeneration    4 (27%)                   3 (20%)      1 (7%)       1 (7%)       2 (13%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Lymph Node                                         (13)         (13)         (14)         (15)         (14)         (14)         
      Hyperplasia                                                                                                       4 (29%)     
      Inflammation, Chronic Active                                                                                      3 (21%)     
      Axillary, Infiltration Cellular                                                                                   1 (7%)      
      Axillary, Infiltration Cellular, Plasma Cell                                                                      1 (7%)      
      Inguinal, Hyperplasia                                                                                             1 (7%)      
      Inguinal, Inflammation, Chronic Active                                                                            1 (7%)      
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    7                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - CONT                                                                                                         
      Mediastinal, Hematopoietic Cell Proliferation                                                                     1 (7%)      
      Mediastinal, Hyperplasia                                                                                          1 (7%)      
      Mediastinal, Infiltration Cellular                                                                                3 (21%)     
      Mediastinal, Infiltration Cellular, Plasma                                                                                    
        Cell                                                                                                            3 (21%)     
      Mediastinal, Inflammation, Chronic Active                                                                         2 (14%)     
   Lymph Node, Mandibular                             (15)         (14)         (15)         (15)         (14)         (13)         
      Hematopoietic Cell Proliferation                                                                                  2 (15%)     
      Hyperplasia                                                   1 (7%)                                              1 (8%)      
      Hyperplasia, Plasma Cell                                                   1 (7%)                    1 (7%)                   
      Infiltration Cellular                                                                                             4 (31%)     
      Infiltration Cellular, Plasma Cell                                                                                1 (8%)      
   Lymph Node, Mesenteric                             (15)         (14)         (14)         (15)         (15)         (12)         
      Infiltration Cellular                                                                                             1 (8%)      
   Spleen                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Atrophy                                                                    1 (7%)                    1 (7%)       4 (27%)     
      Depletion Cellular                                                         1 (7%)                    1 (7%)                   
      Hematopoietic Cell Proliferation                 1 (7%)       4 (27%)      1 (7%)       2 (13%)      6 (40%)      8 (53%)     
      Hyperplasia, Lymphoid                                         1 (7%)       1 (7%)       1 (7%)       1 (7%)                   
   Thymus                                             (15)         (15)         (14)         (15)         (15)         (15)         
      Atrophy                                          1 (7%)                    1 (7%)                    2 (13%)      5 (33%)     
      Thymocyte, Necrosis                                                                                               1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Epidermis, Skin, Site of Application,                                                                                         
        Hyperplasia                                                                           6 (40%)     14 (93%)     15 (100%)    
      Epidermis, Skin, Site of Application,                                                                                         
        Hyperplasia, Focal                                                       1 (7%)                    1 (7%)                   
      Skin, Site of Application, Hyperkeratosis                                  1 (7%)      15 (100%)    14 (93%)     12 (80%)     
      Skin, Site of Application, Hyperplasia                                                                            1 (7%)      
      Skin, Site of Application, Inflammation,                                                                                      
         Chronic Active                                                          1 (7%)       1 (7%)       9 (60%)     12 (80%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    8                                                              
                                                                                                                                   
NTP Experiment-Test: 88133-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                      TRIMETHYLOLPROPANE TRIACRYLATE (TMPTA)                          Date: 07/12/02    
Route: SKIN APPLICATION                                                                                           Time: 08:48:56    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:TGAC (FVB/N) HEMIZYGOUS MALE         0 MG/KG      0.75         1.5          3 MG/KG      6 MG/KG      12 MG/KG        
                                                                MG/KG        MG/KG                                                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (15)         (14)         
      Inflammation, Chronic Active                                  2 (13%)                                             2 (14%)     
      Thrombosis                                                                              1 (7%)                                
      Interstitium, Hyperplasia                        1 (7%)                                                                       
      Interstitium, Inflammation, Chronic Active                                 1 (7%)                                             
      Mediastinum, Infiltration Cellular                                                                                1 (7%)      
      Mediastinum, Inflammation, Chronic Active                                                                         1 (7%)      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (15)         (15)         
      Infarct                                                                                              1 (7%)       1 (7%)      
      Infiltration Cellular                                                                                             1 (7%)      
      Infiltration Cellular, Mononuclear Cell          1 (7%)       1 (7%)                                              1 (7%)      
      Inflammation, Chronic Active                                  2 (13%)      1 (7%)                    1 (7%)       5 (33%)     
      Mineralization                                                                                       1 (7%)                   
      Nephropathy                                      3 (20%)      6 (40%)                                             3 (20%)     
      Glomerulus, Renal Tubule, Dilatation                                                                 1 (7%)                   
      Renal Tubule, Cyst                               1 (7%)       1 (7%)                                              1 (7%)      
      Renal Tubule, Hyperplasia                        1 (7%)                    1 (7%)                    1 (7%)       1 (7%)      
      Renal Tubule, Regeneration                       2 (13%)      1 (7%)       5 (33%)      4 (27%)      4 (27%)                  
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    9                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------